WO2011096808A1 - Use of sialyl oligosaccharides in weight management - Google Patents
Use of sialyl oligosaccharides in weight management Download PDFInfo
- Publication number
- WO2011096808A1 WO2011096808A1 PCT/NL2011/050078 NL2011050078W WO2011096808A1 WO 2011096808 A1 WO2011096808 A1 WO 2011096808A1 NL 2011050078 W NL2011050078 W NL 2011050078W WO 2011096808 A1 WO2011096808 A1 WO 2011096808A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bacteroides
- sialyllactose
- composition
- sialyl
- sialyloligosaccharide
- Prior art date
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 52
- -1 sialyl oligosaccharides Chemical class 0.000 title claims description 25
- 230000037221 weight management Effects 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 79
- 241000606125 Bacteroides Species 0.000 claims abstract description 57
- 235000013350 formula milk Nutrition 0.000 claims abstract description 57
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 29
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 27
- 235000016709 nutrition Nutrition 0.000 claims abstract description 25
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 24
- 208000008589 Obesity Diseases 0.000 claims abstract description 16
- 235000020824 obesity Nutrition 0.000 claims abstract description 16
- 206010033307 Overweight Diseases 0.000 claims abstract description 13
- 235000005911 diet Nutrition 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 230000000378 dietary effect Effects 0.000 claims abstract description 8
- 238000011161 development Methods 0.000 claims abstract description 6
- 239000002417 nutraceutical Substances 0.000 claims abstract description 5
- 235000021436 nutraceutical agent Nutrition 0.000 claims abstract description 5
- 230000001603 reducing effect Effects 0.000 claims abstract description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 33
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 33
- 235000013336 milk Nutrition 0.000 claims description 13
- 239000008267 milk Substances 0.000 claims description 13
- 210000004080 milk Anatomy 0.000 claims description 13
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims description 11
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 claims description 11
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims description 10
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims description 10
- 241000606124 Bacteroides fragilis Species 0.000 claims description 10
- 241000606215 Bacteroides vulgatus Species 0.000 claims description 10
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims description 10
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims description 10
- 241001135228 Bacteroides ovatus Species 0.000 claims description 9
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- 241000606210 Parabacteroides distasonis Species 0.000 claims description 7
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 7
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 7
- 102000011632 Caseins Human genes 0.000 claims description 6
- 108010076119 Caseins Proteins 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000005018 casein Substances 0.000 claims description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 5
- 235000021240 caseins Nutrition 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 235000020218 follow-on milk formula Nutrition 0.000 claims description 4
- 235000020209 toddler milk formula Nutrition 0.000 claims description 4
- MKNNYTWMAUAKMA-FHHHURIISA-N (2s,4s,5r,6r)-5-acetamido-2-[(2s,3r,4s,5s,6r)-2-[(2r,3s,4r,5r)-5-amino-1,2,4-trihydroxy-6-oxohexan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1r,2r)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](N)C=O)O[C@H](CO)[C@@H]1O MKNNYTWMAUAKMA-FHHHURIISA-N 0.000 claims description 3
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 3
- FNCPZGGSTQEGGK-DRSOAOOLSA-N 3'-Sialyl-3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 FNCPZGGSTQEGGK-DRSOAOOLSA-N 0.000 claims description 3
- INZOTETZQBPBCE-NYLDSJSYSA-N 3-sialyl lewis Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@H](O)CO)[C@@H]([C@@H](NC(C)=O)C=O)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 INZOTETZQBPBCE-NYLDSJSYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 102000010445 Lactoferrin Human genes 0.000 claims description 3
- 108010063045 Lactoferrin Proteins 0.000 claims description 3
- SXMGGNXBTZBGLU-IBUUTZGMSA-N Sialyllacto-N-neotetraose c Chemical compound O([C@H]([C@@H]([C@@H](O)[C@H]1O)O)O[C@H]2[C@H](O)[C@H]([C@@H](O[C@@H]2CO)O[C@@H]2[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]2O)O)NC(=O)C)C1CO[C@]1(C(O)=O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O1 SXMGGNXBTZBGLU-IBUUTZGMSA-N 0.000 claims description 3
- RPSBVJXBTXEJJG-LURNZOHQSA-N alpha-N-acetylneuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)O1 RPSBVJXBTXEJJG-LURNZOHQSA-N 0.000 claims description 3
- IESOVNOGVZBLMG-BUZVEHKISA-N alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@H](CO)[C@@H](O)[C@H]1[C@H](NC(C)=O)[C@@H](O)C[C@@](C(O)=O)(O[C@@H]2[C@H]([C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)O[C@@H]3CO)O)O[C@H](CO)[C@@H]2O)O)O1 IESOVNOGVZBLMG-BUZVEHKISA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- KNWXPODBRXAWBX-PFNBIPCHSA-N disialyllacto-n-fucopentaose ii Chemical compound OC1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](OC2[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO[C@@]1(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C1 KNWXPODBRXAWBX-PFNBIPCHSA-N 0.000 claims description 3
- UUZWLWYXBNTJDG-UHFFFAOYSA-N disialyllacto-n-hexaose i Chemical compound C1C(C(O)C(O)CO)C(NC(=O)C)C(O)OC1(C(O)=O)OC1C(O)C(OC2C(C(OC3C(C(OC(C(O)CO)C(O)C(O)C=O)OC(COC4C(C(O)C(OC5C(C(O)C(O)C(COC6(OC(C(NC(C)=O)C(O)C6)C(O)C(O)CO)C(O)=O)O5)O)C(CO)O4)NC(C)=O)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C1O UUZWLWYXBNTJDG-UHFFFAOYSA-N 0.000 claims description 3
- DUVKOIQTTLSEBM-UHFFFAOYSA-N disialyllacto-n-hexaose ii Chemical compound OCC1OC(OCC2C(C(OC3C(C(OC4C(C(OC5(OC(C(NC(C)=O)C(O)C5)C(O)C(O)CO)C(O)=O)C(O)C(CO)O4)O)C(O)C(COC4(OC(C(NC(C)=O)C(O)C4)C(O)C(O)CO)C(O)=O)O3)NC(C)=O)C(O)C(OC(C(O)CO)C(O)C(O)C=O)O2)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O DUVKOIQTTLSEBM-UHFFFAOYSA-N 0.000 claims description 3
- 229960002442 glucosamine Drugs 0.000 claims description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 3
- 235000021242 lactoferrin Nutrition 0.000 claims description 3
- 229940078795 lactoferrin Drugs 0.000 claims description 3
- ARDCDNROJUBBMX-NJMSAGAYSA-N sialyl lea tetra Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)OC1O[C@H]1C(O[C@H]2[C@@H](C(O[C@]3(OC([C@H](NC(C)=O)[C@@H](O)C3)C(O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@H]([C@@H](O)C=O)[C@@H](O)[C@H](O)CO)O[C@@H]1CO ARDCDNROJUBBMX-NJMSAGAYSA-N 0.000 claims description 3
- 240000008886 Ceratonia siliqua Species 0.000 claims description 2
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 101100354192 Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) exp5 gene Proteins 0.000 claims description 2
- 101100505001 Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) glpO gene Proteins 0.000 claims description 2
- 210000003022 colostrum Anatomy 0.000 claims description 2
- 235000021277 colostrum Nutrition 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- 150000002270 gangliosides Chemical class 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 229940072221 immunoglobulins Drugs 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 241001148536 Bacteroides sp. Species 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 10
- 230000036541 health Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 3
- 125000005630 sialyl group Chemical group 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 description 32
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 23
- 241000186000 Bifidobacterium Species 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 244000005709 gut microbiome Species 0.000 description 14
- 210000003608 fece Anatomy 0.000 description 13
- 239000006041 probiotic Substances 0.000 description 13
- 235000018291 probiotics Nutrition 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 241001608472 Bifidobacterium longum Species 0.000 description 11
- 108010046377 Whey Proteins Proteins 0.000 description 11
- 238000000855 fermentation Methods 0.000 description 11
- 230000004151 fermentation Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000005862 Whey Substances 0.000 description 9
- 102000007544 Whey Proteins Human genes 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 241000186660 Lactobacillus Species 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 235000015872 dietary supplement Nutrition 0.000 description 8
- 244000005706 microflora Species 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 230000000529 probiotic effect Effects 0.000 description 7
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 6
- 240000001929 Lactobacillus brevis Species 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 5
- 235000020247 cow milk Nutrition 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 241000186840 Lactobacillus fermentum Species 0.000 description 4
- 240000006024 Lactobacillus plantarum Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000020256 human milk Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000605059 Bacteroidetes Species 0.000 description 3
- 241001134770 Bifidobacterium animalis Species 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 241000186606 Lactobacillus gasseri Species 0.000 description 3
- 241000186605 Lactobacillus paracasei Species 0.000 description 3
- 241000218587 Lactobacillus paracasei subsp. paracasei Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 125000005629 sialic acid group Chemical group 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 241000186160 Bifidobacterium pseudolongum subsp. globosum Species 0.000 description 2
- 241001112696 Clostridia Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 241000186713 Lactobacillus amylovorus Species 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 241001134659 Lactobacillus curvatus Species 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 241000186612 Lactobacillus sakei Species 0.000 description 2
- 241000186783 Lactobacillus vaginalis Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000001847 bifidogenic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000019722 synbiotics Nutrition 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000277612 Bifidobacterium breve JCM 7017 Species 0.000 description 1
- 241000277613 Bifidobacterium breve JCM 7019 Species 0.000 description 1
- 241000277615 Bifidobacterium breve NCFB 2258 Species 0.000 description 1
- 241000003117 Bifidobacterium breve UCC2003 Species 0.000 description 1
- 241000186020 Bifidobacterium dentium Species 0.000 description 1
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 1
- 241000163581 Bifidobacterium pseudocatenulatum DSM 20438 = JCM 1200 = LMG 10505 Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000316282 Lactobacillus antri Species 0.000 description 1
- 241001069957 Lactobacillus antri DSM 16041 Species 0.000 description 1
- 241001584954 Lactobacillus brevis ATCC 14869 = DSM 20054 Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000316283 Lactobacillus gastricus Species 0.000 description 1
- 241001104421 Lactobacillus gastricus DSM 16045 Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000316281 Lactobacillus kalixensis Species 0.000 description 1
- 241001104454 Lactobacillus kalixensis DSM 16043 Species 0.000 description 1
- 241000186784 Lactobacillus oris Species 0.000 description 1
- 241001104436 Lactobacillus oris DSM 4864 Species 0.000 description 1
- 241001104465 Lactobacillus parabuchneri DSM 5707 = NBRC 107865 Species 0.000 description 1
- 241000535428 Lactobacillus reuteri DSM 20016 Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 241000186870 Lactobacillus ruminis Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000316280 Lactobacillus ultunensis Species 0.000 description 1
- 241001069996 Lactobacillus ultunensis DSM 16047 Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000604373 Ovatus Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000003838 Sialyltransferases Human genes 0.000 description 1
- 108090000141 Sialyltransferases Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000020248 camel milk Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 235000019007 dietary guidelines Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 235000021244 human milk protein Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000021129 infant diet Nutrition 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical class OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 235000020214 lactose-free milk formula Nutrition 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 101150109310 msrAB1 gene Proteins 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000008924 yoghurt drink Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the sialyloligosaccharide is obtained by a method comprising ion exchange technology, as for example in WO 2009/113861.
- ion exchange technology as for example in WO 2009/113861.
- whey permeate streams are used as source of sialyllactose, which is captured selectively from these streams via ion exchange technology.
- B. Bifidobacterium
- B. Bifidobacterium
- B. breve B. lactis Bb-1, B. lactis Bbl2, B. animalis, B. digestivus, B. infantis, B. adolescentis and B. longum.
- Particularly preferred strains are the strain of B. lactis sold by the Christian Hansen company of Denmark under the trade mark Bbl2, Bifidobacterium longum ATCC BAA-999 obtainable from Morinaga Milk Industry Co. Ltd. of Japan under the trade mark BB536, B.
- a single serving of a low calorie nutritional composition e. g. meal replacement, will have a caloric value of less than about 1000 kcal, and preferably between about 200 kcal and about 500 kcal.
- Suitable low calorie nutritional composition may include soft drink, such as juice, smoothie or soy-based drink, or dispersed in foods of any sort, such as, dairy bars, soups, cereals, e.g.
- the composition is a non-fermented composition.
- the compositions of the invention may be provided as high calorie compositions, e. g. high calorie dietary supplement or meal replacement, for instance with a caloric value of more than about 400 kcal, preferably more than about 600 kcal, more preferably more than about 800 kcal.
- An infant formula according to the present invention comprising a sialyl oligosaccharide, preferably a sialyllactose, can contribute to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an infant having or at risk for overweight or obesity, e.g. at a later stage in life.
- Infant formulas are commonly used today to provide supplemental or sole source nutrition early in life. These formulas contain protein, carbohydrate, fat, vitamins, minerals, and other nutrients. They are commercially available as powders, ready-to-feed liquids, and liquid concentrates. There are currently a variety of commercially available infant formulas, each one designed to meet the specific nutritional needs of a particular infant group. Milk-based infant formulas, for example, represent the majority of commercially available infant formulas.
- Proteins suitable for use in the base formulas herein include hydrolyzed, partially hydrolyzed, and non-hydrolyzed or intact proteins or protein sources, and can be derived from any known or otherwise suitable source such as milk (e.g., casein, whey, human milk protein), animal (e.g., meat, fish), cereal (e.g., rice, corn), vegetable (e.g., soy), or combinations thereof.
- the composition of the invention comprises a whey fraction comprising the whey proteins a-lactalbumin (a- LA) and casein macropeptide (CMP), wherein the weight ratio between a-LA and CMP is > 2.
- the composition of the invention comprises a whey fraction comprising the whey proteins a-lactalbumin (a-LA) and casein macropeptide (CMP), wherein the weight ratio between a-LA and CMP is ⁇ 2.
- Vitamins and similar other ingredients suitable for use in the base formulas include vitamin A, vitamin D, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, vitamin B12, niacin, folic acid, pantothenic acid, biotin, vitamin C, choline, inositol, salts and derivatives thereof, and combinations thereof.
- Minerals suitable for use in the base formulas include calcium, phosphorus, magnesium, iron, zinc, manganese, copper, chromium, iodine, sodium, potassium, chloride, and combinations thereof.
- a pharmaceutical composition as provided herein, e.g. clinical product, and nutritional compositions of the invention, e. g. dietary supplements, may be provided in the form of soft gel, sachets, powders, syrups, liquid suspensions, emulsions and solutions in convenient dosage forms.
- Oral pharmaceutical or dietary supplement forms may be made by conventional compounding procedures known in the pharmaceutical art, that is, by mixing the active substances together with edible pharmaceutical acceptable solid or liquid carriers and/or excipients, e. g.
- the use of a sialyl-oligosaccharide is provided for the manufacture of an infant formula for reducing the risk of development of overweight or obesity of an infant in later life.
- the formula may contain any of the components described herein above.
- the infant formula can be formulated to be administered to an infant of between 0 and 3 months of age, between 3 and 6 months of age, between 6 and 9 months of age, between 9 and 12 months of age or between 12 and 24 months of age.
- Figure 1 Effects of sialyllactose and GOS on micoflora composition of batch cultures inoculated with a pool of adult faeces.
- the panels show the total amount of bacteria per vessel (A), bacteroides (B), and bifidobacteria (C) numbers quantified by QPCR. Values shown are averages of two separate runs, with error bars indicating the deviation of the mean of the two measurements.
- Figure 2 Effects of sialyllactose and GOS on micoflora composition of batch cultures inoculated with a pool of adult faeces.
- Figure 3 Effects of sialyllactose and GOS on micoflora composition of batch cultures inoculated with a pool of infant faeces as described in example 2.
- GOS Vivinal GOS, FrieslandCampma Domo
- sialyllactose Vivinal SL, FrieslandCampma Domo
- a pH-controlled batch fermentation model which represents the distal part of the colon, was used to measure the effect of the oligosaccharides on the composition of the microflora, and the production of short chain fatty acids and lactate.
- Faecal samples were obtained from 16 adult volunteers (average BMI 23,4, range 18,0 - 27,8) free of known gastrointestinal disorders. None of the volunteers had taken prebiotic products within a three-month period prior to sampling. Individual faecal samples were diluted to a 1 in 10 weight/weight mixture using 0.1M, pH7, phosphate buffered saline (PBS) (Sigma laboratories, Gillingham, Dorset, UK) at pH7.4 and pooled. The PBS was reduced overnight in an anaerobic cabinet (10% H2, 10% CO2, 80% N2). This mixture was then homogenised for 120 seconds (Seward Stomacher 80 Biomaster), at normal speed, in the stomacher. The faecal slurry was aliquotted and frozen. The faecal slurry was thawed just prior to the start of the experiment and used to inoculate the batch cultures. pH Controlled, Stirred batch cultures
- Chemostat nutrient medium was prepared containing the following ingredients: Peptone water 2g/l (Oxoid, Basingstoke, UK), yeast extract 2g/l (Oxoid), NaCl O.lg/1 (Fisher, Loughborough, UK), K2HPO4.3H20 0.05g/l (BDH, Poole, UK), KH2PO4 0.04g/l (BDH), MgS0 4 .7H 2 0 O.Olg/1 (Sigma), CaCl2.2H 2 0 0.005g/l (BDH), NaHCOs 2g/l (Sigma), Tween 80 (BDH) 2ml, Hemin 0.02g/l, Vitamin Ki ⁇ (Sigma), Cystiene HC1 0.5g/l (Oxoid), Bile Salts 0.5g/l (Oxoid), Resazarin 4ml/l (Sigma), pH7.
- the chemostat nutrient medium autoclaved, then aseptically poured into the sterile batch culture vessels. This was left overnight with nitrogen pumping through the vessel to provide an anaerobic environment. 0.5ml of 10% cysteine-HCl was added to aid reduction of the medium. pH meters (Electrolab pH controller, Tewksbury, UK) were set to regulate the vessels between pH6.8 and pH7 by the addition of 0.5M HC1 or 0.5M NaOH. The vessels were maintained at 37°C, and were stirred using magnetic stirrers.
- Escherichia coli, Lactobacilli, Clostridia, Bifidobacteria, and Bacteroides were based on 16S rDNA gene sequences, retrieved by http ://gr eengene s . lfal, go v website. From these sequences forward primers, reverse primers and TaqMan probes were designed using the Primer Express software. To check specificity, the selected primers and probes were compared to all available 16S rDNA gene sequences using the BLAST database search program. Applied Biosystems manufactured primers and probes.
- Example 2 Effect of sialyl oligosaccharide on baby faeces microflora composition.
- This example demonstrates the effect of oligo- and polysaccharides on the microbial population of baby faeces by in vitro fermentation.
- the experiments were essentially carried out as described in Example 1, only now with a batch of in vitro prefermented infant faeces.
- the testgroups included a control vessel, a vessel containing purified GOS (10 g/L oligosaccharide), and a vessel containing purified SL (lOg/L
- Figure 3B shows the amounts of Bacteroides present during batch fermentation. Bacteroides were stimulated by SL and GOS when compared to the control fermentation. When corrected for the total bacteria numbers a stimulation of
- Figure 4A Bacteroides was most consistent and prominent for SL (Figure 4A).
- Figure 3A shows that the total growth of bacteria was stimulated by GOS and SL up to a 2-5 fold increase during 24 h. The total bacteria count of control was stable.
- Figure 3C illustrates that the Bifidobacteria were stimulated by GOS and SL compared to the Bifidobacteria in the control vessel present. After correction for the total bacteria count (Figure 4B), there is an increase of the amount of Bifidobacteria during the first part of the fermentation (till 9 h), whereas in the second part of the fermentation the amount of Bifidobacteria decreased.
- SL can also increase the amount of Bacteroides in infant faeces.
- Example 3 Species analysis using DNA-Chip
- Short oligonucleotide sequences (approx 20 nt) were used with a melting temperature of 60°C according to the Wallace rule for which a one nucleotide mismatch already resulted in an absence (or very strong decrease) of signal after hybridization.
- Results are shown in Table 2. The numbers are based on duplicate analysis, and represent the fold increase over background level.
- Bacteroides 10 75 30 55 group The results shown in Table 2 demonstrate that SL strongly enhances the growth of Bacteroides, in particular B. fragilis, B. thetaiotaomicron and B. vulgatus. The prebiotic effect of SL on Bacteroides was stronger than that exerted by GOS and remained intact when SL was used in combination with the bifidogenic GOS.
- Table 3 shows the composition of three exemplary nutritional formulas according to the invention, e.g. infant formulas for the age group between 0-6 months, for reducing the risk of development of overweight or obesity of an infant in later life.
Abstract
The invention relates to prebiotics and the use thereof for promoting human health. In particular, it relates to milk-, whey- or egg-derived oligosaccharides capable of enhancing the relative abundance of beneficial micro-organisms. Provided is the use of a sialyl - oligosaccharide for the manufacture of a dietetic, nutraceutical, pharmaceutical or nutritional composition, like an infant formula, for treating or preventing a condition associated with a reduced amount of Bacteroides ssp. in the gastrointestinal tract. Also provided is an infant formula for reducing the risk of development of overweight or obesity of an infant in later life. Said composition comprises living Bacteroides ssp. in an amount of at least 10+5cfu/g dry weight of the composition.
Description
Title: Use of sialyl oligosaccharides in weight management.
The invention relates to prebiotics and the use thereof for promoting human health. In particular, it relates to milk-derived oligosaccharides capable of enhancing the relative abundance of beneficial micro-organisms.
There is increasing awareness that the human gut microflora plays a critical role in maintaining host health, both within the gastrointestinal tract and, through the systemic absorption of metabolites. An "optimal" gut microflora establishes an efficient barrier to the invasion and colonisation of the gut by pathogenic bacteria, produces a range of metabolic substrates which in turn are utilized by the host (e.g. vitamins and short chain fatty acids) and stimulates the immune system in a non- inflammatory manner. Although little is known about the individual species of bacteria responsible for these beneficial activities, it is generally accepted that the bifidobacteria and lactobacilli constitute important components of the beneficial gut microflora. A number of diet-based microflora management tools have been developed and refined over recent decades including probiotic, prebiotic and synbiotic approaches. Each aims to stimulate numbers and/or activities of the bifidobacteria and lactobacilli within the gut microflora.
Of particular interest is the use of the gut microbiome as a therapeutic target for weight management. The obese population is growing worldwide as energy intake exceeds energy expenditure. Consequently, more people are at risk of developing obesity-related diseases such as diabetes mellitus type 2 and cardiovascular diseases. It is known in the art that there is a relationship between the diversity of the gut microbiota and obesity and that the energy balance of a subject may be modulated by altering the subject's gut microbiota population. See for example WO2007/043933 and EP1974734.
WO2008/076696 discloses that modulation of the relative abundance of bacteria within the Bacteroidetes or the Firmicutes division can be used to modulate the energy balance in a subject. Among others, WO2008/076696 teaches to decrease energy harvesting, decrease body fat, or promote weight loss by increasing the
relative abundance of Bacteriodetes. It was thus proposed to administer a probiotic composition comprising Bacteriodetes to a subject.
Prebiotic supplements have also been implicated in weight management. Prebiotics have a number of advantages over probiotics; principally the fact that they are not alive means that they can be processed into a much wider range of foods than can the fragile probiotics. Furthermore, prebiotics do not share the problem of probiotic survival upon ingestion by the consumer. Since prebiotics stimulate growth of bacteria that are already present in the gut, they can be seen as more natural ingredients than probiotics, which necessitate administration of extraneous bacteria.
Parnell and Reimer (American Journal of Clinical Nutrition, June 2009,
Volume 89, Number 6, Pages 1751-1759), recruited 48 overweight and obese, but otherwise healthy, adults and randomly assigned them to receive daily supplements of oligofructose (21 grams) or placebo (maltodextrin) for 12 weeks. At the end of the study, people in the oligofructose group lost on average 1.03 kg of body weight, while people in the placebo group gained an average of 0.45 kg. While levels of ghrelin were suppressed by the prebiotic supplements, and PPY levels increased, no effects were observed on the satiety hormone glucagon-like peptide 1 (GLP-1). Furthermore, the oligofructose group reported a reduction in self-reported caloric intake, in addition to decreased levels of glucose and a mirroring effect on insulin concentrations.
EP2143341 discloses the use of an N-acetylated oligosaccharide, a galactose- oligosaccharide and a sialylated oligosaccharide in the manufacture of a nutritional composition such as an infant formula, for administration to an infant in the first six months of life to reduce the risk of obesity later in life.
Critical to the prebiotic concept is their selective fermentation within the gut microflora by what are seen as beneficial genera. Various preferred relationships between prebiotics and beneficial bacteria have been reported. For example, oligofructose can be utilized efficiently by Lactobacilli and Bifidobacteria.
WO2007/101675 relates to preparations comprising a probiotic and a prebiotic mixture which is specifically designed to enhance the efficiency and the efficacy of the probiotic and to food products comprising said preparation. Thus, prebiotics are suitably used to modulate the relative abundance of a certain micro-organism of interest.
So far, the effects of prebiotic oligosaccharides on Bacteriodes spp. are limited to suppressive or reducing effects. For example, Tanaka et al. (Bif. Microflora 1983; 2: 17-24) reported that numbers of Bacteriodes decreased significantly upon ingestion of 10 g/day of trans-galacto-oligosaccharides (TOS). A reduction in Bacteriodes spp. was also observed after ingestion of lactulose (Ballongue et al. , Scand J Gastroenterol 1997; 32:41-4) or FOS (Gibson et al, Gastroenterology 1995; 108:975-82).
Recognizing the therapeutic potential of modulating the amount of
Bacteroidetes in the gut, e.g. in the treatment of obesity, the present inventors set out to identify a prebiotic capable of enriching the gut microbiota for bacteria within the Bacteroidetes division. In particular, they aimed at identifying prebiotics derivable from ruminant's milk which are useful for enriching the gut microflora for Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides prevotalla group, Bacteroides thetaiotaomicron and/or Bacteroides vulgatus.
It was surprisingly observed that a milk-derived sialic acid-containing oligosaccharide is capable of selectively promoting the growth of various Bacteroides species in adult and infant human faeces. This finding opens up a new window of application for sialyl oligosaccharides, in particular as prebiotic substance to enhance growth of Bacteroides ssp. in the gastrointestinal tract.
In one aspect, the invention provides a dietetic, nutritional or pharmaceutical composition, preferably formulated for oral or enteral administration, comprising at least one sialyl oligosaccharide in an amount effective to increase the relative abundance of Bacteroides ssp. in the gastrointestinal tract, such as Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides prevotalla group, Bacteroides thetaiotaomicron and/or Bacteroides vulgatus. In a specific embodiment, it comprises at least one sialyl oligosaccharide in an amount effective to increase the relative abundance of Bacteroides fragilis, Bacteroides ovatus, Bacteroides
thetaiotaomicron and/or Bacteroides vulgatus in the gastrointestinal tract.
WO2008/076696 discloses a nutritional composition comprising oligofructose and siallyllactose and its use for increasing the amount of Bifidobacteria. Whereas WO2008/076696 generally states that no effect on Bacteroides was observed, no information is given about which species were investigated.
As used herein, the term "sialyl oligosaccharide" means an oligosaccharide having at least one sialic acid moiety with associated charge. Sialic acids comprise a
family of about 40 derivates of the nine carbon sugar neuramic acid. Sialic acid is the generic term for the N- or O-substituted derivatives of neuraminic acid. Milk contains sialic acid moieties in different forms. It can be present as a constituent of water soluble free oligosaccharides (e.g. sialyllactose), or bound to either glycoproteins such as lactoferrin and κ-casein and/or glycolipids (GD3 and GM3). The present invention is preferably practiced using a sialyloligosaccharide selected from the group consisting of sialyloligosaccharides derived from milk (e.g. cow, goat, camel, human milk), whey or egg. The sialyloligosaccharides can for instance be directly separated from milk, whey or egg or produced from components derived here from. Suitable
sialyloligosaccharides for use in the present invention are disialyllacto-iV-tetraose, 3'- sialyllactose, 6'-sialyllactose, 3'-sialyllactosamine, 6'-sialyllactosamine, 3'-sialyl-3- fucosyllactose, sialyllacto-iV-tetraose a, sialyllacto-iV-tetraose b, sialyllacto-iV-tetraose c, disialyllactose, 3'-sialyl Lewis A, 3'-sialyl Lewis X, disialyllacto-N-hexaose I, disialyllacto-N-hexaose II, sialyl Lea tetra, sialyllacto-N-neotetraose c, disialyllacto-N- fucopentaose II, and any combination thereof. An exemplary commercial preparation comprising egg yolk sialyl oligosaccharides is Sunsial E from Tayio Kaguku Co, Japan. Another exemplary preparation is Vivinal SL, a product comprising sialyllactose (FrieslandCampina Domo, the Netherlands)
In the sialyl oligosaccharides of human milk, sialic acid is attached to a penultimate galactose residue or N-acetylglucosamine residue via a2-3 or a2-6 linkage formed by the action of sialyl transferase (Kunz et al., Annu Rev Nutr.
2000;20:699-722, Asakuma et al, Biosci Biotechnol Biochem. 2007; 71:1447-51).
Sialyllactose represents the main part of the sialyl-oligosaccharide fraction in human and cow's milk. In one embodiment, the invention provides a dietetic, nutritional or pharmaceutical composition comprising sialyllactose in an amount effective to increase the relative abundance of Bacteroides ssp. in the gastrointestinal tract. For example, (partially) purified 3'-sialyllactose, 6'-sialyllactose or a mixture thereof may be used. Sialyl oligosaccharide, such as sialyllactose, may be enzymatically produced. In a specific aspect, a product of FrieslandCampina Domo (The Netherlands) with the tradename Vivinal SL, comprising about 6 weight% sialyllactose, is used as source of the prebiotic sialyl-oligosaccharide.
The sialyloligosaccharides 3' sialyllactose and /or 6' sialyllactose may be isolated e.g. by chromatographic or filtration technology from a natural source such as
animal milks, for example human milk, cow milk, goat milk, camel milk, or whey. Preferred sources include whey and cow's milk. The concentration of lactose in cow's milk is about 40 to 60 g/litre, whereas the concentration of sialylated oligosaccharides in cow's milk is between 30 and 60 mg/ litre. In this latter fraction, sialyllactose is the most abundant oligosaccharide. In a preferred embodiment, the sialyloligosaccharide is obtained by a method comprising ion exchange technology, as for example in WO 2009/113861. For example, whey permeate streams are used as source of sialyllactose, which is captured selectively from these streams via ion exchange technology.
Subsequent downstream processing may include removal of remaining minerals and water, and a drying step.
The structures of sialic acid, 3'-sialylactose and 6' -sialyllactose are presented in table 1.
Table 1
A composition according to the invention finds its use as a dietetic, nutritional, nutraceutical or pharmaceutical composition. In a particular aspect, it can be used in the treatment or prevention of overweight or obesity in a subject, preferably a human subject. In humans, waist circumference measurement and body mass index (BMI) are the recommended ways to estimate body fat. BMI values from 18.5 to 24.9 are normal. Overweight is defined as a body mass index of 25.0 to less than 30.0
(consistent with U.S. Dietary Guidelines for Americans). A BMI of about 25 kg/m2 corresponds to about 10 percent over ideal body weight. Obesity is defined as a BMI of 30.0 or greater (consistent with criteria of the World Health Organization), or about 30 pounds or more overweight. Extreme obesity is defined as a BMI of 40 or greater.
To achieve the desired health effect through enriching the gut microflora for Bacteroides, known to decrease energy harvesting, the composition comprises at least one sialyloligosaccharide in an amount sufficient or effective to increase the relative abundance of a Bacteroides ssp. in the gastrointestinal tract. A composition according to the present invention can contribute to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal, preferably a human, having or being at risk for overweight or obesity, comprising administering to the animal a composition comprising at least one sialyloligosaccharide. The relative abundance of Bacteroides ssp. refers to the quantitative contribution of Bacteroides ssp. to the total number of bacteria. For weight loss, the abundance may be altered by an increase of from about 100% to about 5000%, from about 200% to about 5000%, from about 300% to about 5000%, from about 400% to about 5000%, from about 500% to about 5000%, from about 600% to about 5000%, from about 700% to about 5000%, or from about 800% to 5000%. A method for determining the relative abundance of gut Bacteroides is described in WO2008/076696. Stated in another way, for weight loss, the abundance may be altered by an increase of about a two fold difference to about a fifty fold difference, of about a three fold difference to about a fifty fold difference, of about a four fold difference to about a fifty fold difference, of about a five fold difference to about a fifty fold difference, or of about a six fold difference to about a fifty fold difference
In one embodiment, the composition is capable (i.e. upon ingestion) of increasing the relative abundance of a Bacteroides ssp., preferably Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides prevotalla group,
Bacteroides thetaiotaomicron and/or Bacteroides vulgatus, by at least 2-fold, preferably at least 4-fold, or even at least 6-fold. This effect may be observed after several hours up to several days after ingestion. In one aspect, the composition comprises at least one sialyl oligosaccharide in an amount of 0.005 - 20 grams per dose unit, for example a daily dose unit. A dose unit may consist of 0,2-500 grams, depending among others on the type of composition (solid, liquid), intended use (complete food, pharmaceutical composition, food supplement) and/or the intended consumer (adult, infant). For example, sialyl oligosaccharide may be present in an amount of 0.01— 10 gram per daily dose unit or per 100 grams or ml of composition. In another aspect, the composition comprises at least one sialyl oligosaccharide in an amount of 0.005-20 grams per 100 ml liquid composition, and preferably 0.1-10 grams per 100 ml liquid composition.
In one embodiment, the composition comprises the one or more
sialyloligosaccharide(s) as the sole prebiotic compound(s). In another embodiment the composition may contain one or more further (i.e. other than sialyloligosaccharides) prebiotic ingredients known in the art. Examples of suitable prebiotics are fructo and/or galacto-oligosaccharides, with short or long chains, inulin, fucose-containing oligosaccharides, beta glycans, carob flour, gums, pectins, galactans with short or long chains, glucosamine galactans and other glucosamine-containing oligosaccharides and nucleotides. In one preferred embodiment, a composition comprises sialyllactose and GOS, optionally as the sole prebiotic oligosaccharides. The composition may also contain one or more milk or whey derived components. Examples are sialic acid, a- Lactalbumin, lactoferrin, glycoproteins, casein macropeptide, gangliosides, phospholipids, colostrum, immunoglobulins, milk calcium and nucleotides.
In addition to the sialyloligosaccharide having a prebiotic effect on Bacteroides resident in the Gl-tract, a composition according to the invention may also be supplemented with one or more living Bacteroides ssp. (i.e. not inactivated, non- fragmented and capable of colonizing the intestinal tract at least transiently), such that the relative abundance of Bacteroides in the intestinal tract is even further enhanced. Preferred species include Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides prevotalla group, Bacteroides thetaiotaomicron and/or Bacteroides vulgatus. Typically the probiotics are added in an amount of at least 10
exp5 cfu/g dry weight of formula, preferably 10 exp6, more preferably 10 exp 7 cfu/g although generally even larger amounts are preferred, for example up to 10expl2 cfu/g of formula. In contrast to the present invention, WO2010/002241 discloses a nutritional composition comprising inactivated (e.g. heat killed) Gram-negative bacteria and/or bacterial cell fragments in an amount of less than 10 exp3 cfu per gram dry weight of formula and its use in providing nutrition to an infant delivered via caesarean section. According to WO2010/002241, the non-living, inactivated bacteria are thought to induce tolerance of the intestinal tract against colonisation with Gram-negative bacteria. The inactivated bacterial material is preferably combined with one or more non- digestible oligosaccharides selected from fructo- oligosaccharides, galacto-oligosaccharides and sialic acid comprising oligosaccharides. Importantly, the combined use of a sialyl oligosaccharide and living Bacteroides ssp. is not taught or suggested. In contrast, WO2010/002241 teaches to avoid the inclusion of live bacteria.
Of course, other beneficial probiotic strains may also be included in a composition provided herein, including specific strains of the genera Lactobacilli and Bifidobacteria that have been found to be able to colonise at least transiently the intestinal mucosa, to reduce the capability of pathogenic bacteria to adhere to the intestinal epithelium, to have immunomodulatory effects and/or to assist in the maintenance of well-being. Thus, alternative or additional probiotic bacterial strains include a lactobacillus or a bifidobacterium. Preferably strains which produce only L (+) lactic acid are used. Exemplary Lactobacillus (L.) species are L. rhamnosus, L. paracasei, L. amylovorus, L. ultunensis, L. acidophilus, L. kalixensis, L. delbrueckii subsp. Lactis, L. oris, L. fermentum, L. gastricus, L. antri, L. fermentum, L.
parabuchneri, L. brevis, L. plantarum, L. curvatus, L. sakei, L. gasseri, L. vaginalis, L. acidophilus, L. johnsonii, L. casei, L. salivarius and Lactobacillus reuteri. Particularly preferred strains are Lactobacillus rhamnosus ATCC 53103, Lactobacillus rhamnosus CGMCC 1.3724, Lactobacillus reuteri ATCC 55730, L. amylovorus DSM20552, L. ultunensis DSM16047, L. acidophilus ATCC4356, L. kalixensis DSM16043, L.
delbrueckii subsp. lactis DSM20073, L. oris DSM4864, L. reuteri DSM20016, L.
reuteri DSM20053, L. fermentum DSM20055, L. gastricus DSM16045, L. antri DSM16041, L. paracasei subsp. paracasei 43362, L. paracasei subsp. paracasei 43332, L. paracasei subsp. paracasei 43338, L. parabuchneri DSM5707, L. brevis DSM20054,
L. plantarum NCD0326, L. plantarum NCIMB8826, L. curvatus NCD02739, L. sakei DSM20100, L. ruminis L5, L. gasseri SR21, L. vaginalis SR213, L. fermentum SR22, L. gasseri CR159, L. RC- 14, L. rhamnosis GR- 1, L. plantarum 299V and Lactobacillus paracasei CNCM 1-2116. Examples of preferred Bifidobacterium (B.) species are B. lactis, B. breve B. lactis Bb-1, B. lactis Bbl2, B. animalis, B. digestivus, B. infantis, B. adolescentis and B. longum. Particularly preferred strains are the strain of B. lactis sold by the Christian Hansen company of Denmark under the trade mark Bbl2, Bifidobacterium longum ATCC BAA-999 obtainable from Morinaga Milk Industry Co. Ltd. of Japan under the trade mark BB536, B. Adolescentis CIP 64.61, B. Adolescentis DSM 20083, B. Adolescentis NCFB 2229, B. Adolescentis NCFB 2204, B. Adolescentis LMG 10502, B. animalis JCM 20097, B. animalis DSM 20105, B. bifidum NCIMB 8810, B. bifidum LMG 11041, B. breve UCC2003, B. breve JCM 7017, B. breve JCM 7019, B. breve CCUG 43878, B. breve NCIMB 8815, B. breve NCFB 2258, B. breve NCFB 2257, B. breve NCFB 11815, B. dentium NCFB 2843, B. longum JCM 7050, B. longum JCM 7052, B. longum JCM 7056, B. longum CIP 64.63, B. longum CCUG 30698, B. longum NCIMB 8809, B. longum CCUG 15137, B. longum JCM 7053, B. longum / infantis CCUG 18157, B. infantis NCDO 2205, B. pseudocatenulatum LMG 10505, B. pseudocatenulatum NCIMB 8811, B. pseudolongum NCIMB 2244, B.
pseudolongum DSM 20095, B. globosum JCM 5820, B. globosum JCM 7092, B.
thermophilum JCM 7027. In a specific embodiment, the combination of B. lactis strain deposited under ATCC number 27536 and the L. casei strain deposited under ATCC number 55544 is used (see WO2008/056983 in the name of the applicant). In another specific embodiment, the combination of B. /acitsBB12 and L. paracasei CRL431is used.
The composition of the invention may be in any form suitable for human
administration, and in particular for administration in any part of the
gastrointestinal tract. Enteral administration of the compositions of the invention, and preferably oral administration, and administration through a tube or catheter, are all covered by the present invention. It can be a solid, semi-solid or liquid nutritional formulation, such as infant nutrition (infant formula, follow on formula or growing up milk), nutraceutical, nutritional or dietary supplement, functional food, beverage product, meal replacement, or food additive. Such nutritional compositions
may be nutritionally complete, i.e. may include vitamins, minerals, trace elements as well as nitrogen, carbohydrate and fatty acid sources so that they may be used as the sole source of nutrition supplying essentially all the required daily amounts of vitamins, minerals, carbohydrates, fatty acids, proteins and the like. Accordingly, the compositions of the invention may be provided in the form of a nutritionally balanced composition, e. g. a complete formula diet or a complete meal, e. g. suited for oral or tube feeding. Alternatively, the composition of the invention may be provided as part of a meal, i.e. a nutritional or dietary supplement, e. g. in the form of a health drink. It may be desirable to provide the composition of the invention in the form of a low calorie composition, e. g. meal replacement. In this case the nutritional composition, e.g. meal replacement, is preferably low fat, i.e. less than about 10 en%, or substantially fat-free, i.e. less than about 2.5 en% contributed by fat, such as about 2 en% fat, based on the total caloric content of the composition. Suitably, a single serving of a low calorie nutritional composition, e. g. meal replacement, will have a caloric value of less than about 1000 kcal, and preferably between about 200 kcal and about 500 kcal. Suitable low calorie nutritional composition may include soft drink, such as juice, smoothie or soy-based drink, or dispersed in foods of any sort, such as, dairy bars, soups, cereals, e.g. breakfast cereals, muesli, candies, tabs, cookies, biscuits, crackers, such as a rice crackers, and dairy products, such as milk-shake, yoghurt drink, yoghurts and fruit drinks. In one embodiment, the composition is a non-fermented composition. Alternatively, the compositions of the invention may be provided as high calorie compositions, e. g. high calorie dietary supplement or meal replacement, for instance with a caloric value of more than about 400 kcal, preferably more than about 600 kcal, more preferably more than about 800 kcal.
In a specific aspect, the composition is an infant formula (including follow on formula or growing up milk). The bacterial composition in the infant digestive tract (also called the intestinal microflora) follows a pattern of change starting in the newborn, and varies depending on the infant diet. Development of the infant's intestinal microflora is initiated at birth. The aseptic, or sterile, digestive tract of the foetus is inoculated with bacteria during birth by the mother's intestinal and vaginal microflora. During the first week of life, enterobacteria and enterococci predominate in the gut of both breastfed and formula-fed infants. After this, the microflora changes
rapidly. Some of the changes that occur depend on whether the infant is breastfed or formula-fed. An infant formula according to the present invention comprising a sialyl oligosaccharide, preferably a sialyllactose, can contribute to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an infant having or at risk for overweight or obesity, e.g. at a later stage in life. Infant formulas are commonly used today to provide supplemental or sole source nutrition early in life. These formulas contain protein, carbohydrate, fat, vitamins, minerals, and other nutrients. They are commercially available as powders, ready-to-feed liquids, and liquid concentrates. There are currently a variety of commercially available infant formulas, each one designed to meet the specific nutritional needs of a particular infant group. Milk-based infant formulas, for example, represent the majority of commercially available infant formulas. Soy-based formulas also represent a large portion of the infant formula market by offering an alternative to milk-based formulas, especially in milk- intolerant infants. Lactose-free formulas are also available and can be useful in those infants with lactose sensitivity. Infant formulas with amino acids or partially hydrolyzed proteins are also available for certain infants.
The base infant formula comprises fat, protein, carbohydrate, vitamins and minerals, all of which are selected in kind and amount to provide a sole source of nutrition for the targeted infant or defined infant population. For example, the infant formula may be formulated for an infant of between 0 and 3 months of age, between 3 and 6 months of age, 6 and 9 months of age or 9 and 12 months of age (infant formula for infants between 6 and 12 months age are often called follow on formula). There are also infant formula for infants older than 12 months and even older than 24 months, and up to an age of 6 years (often called growing up milk). Infant formulas for use as base formulas include any known ready-to-feed infant formula, or any nutritional formula suitable for use in infants, provided that such a formula is a sole source nutritional having caloric density and osmolality values within the ranges defined herein. Many different sources and types of carbohydrates, fats, proteins, minerals and vitamins are known and can be used in the base formulas herein, provided that such nutrients are compatible with the added ingredients in the selected formulation and are otherwise suitable for use in an infant formula. Carbohydrates suitable for use in the base formulas herein may be simple or complex, lactose-containing or
lactose-free, or combinations thereof, non-limiting examples of which include hydrolyzed, intact, naturally and/or chemically modified cornstarch, maltodextrin, glucose polymers, sucrose, corn syrup, corn syrup solids, rice or potato derived carbohydrate, glucose, fructose, lactose, high fructose corn syrup and indigestible oligosaccharides such as fructooligosaccharides (FOS), galactooligosaccharides (GOS), and combinations thereof. Particularly preferred is an infant formula comprising the combination of sialyllactose and GOS.
Proteins suitable for use in the base formulas herein include hydrolyzed, partially hydrolyzed, and non-hydrolyzed or intact proteins or protein sources, and can be derived from any known or otherwise suitable source such as milk (e.g., casein, whey, human milk protein), animal (e.g., meat, fish), cereal (e.g., rice, corn), vegetable (e.g., soy), or combinations thereof. In one embodiment, the composition of the invention comprises a whey fraction comprising the whey proteins a-lactalbumin (a- LA) and casein macropeptide (CMP), wherein the weight ratio between a-LA and CMP is > 2. In another embodiment, the composition of the invention comprises a whey fraction comprising the whey proteins a-lactalbumin (a-LA) and casein macropeptide (CMP), wherein the weight ratio between a-LA and CMP is < 2.
Proteins for use herein can also include, or be entirely or partially replaced by, free amino acids known for or otherwise suitable for use in infant formulas, non-limiting examples of which include alanine, arginine, asparagine, carnitine, aspartic acid, cystine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, taurine, threonine, tryptophan, taurine, tyrosine, valine, and combinations thereof. These amino acids are most typically used in their L-forms, although the corresponding D -isomers may also be used when nutritionally equivalent. Racemic or isomeric mixtures may also be used.
Fats suitable for use in the base formulas herein include coconut oil, soy oil, corn oil, olive oil, safflower oil, high oleic safflower oil, algal oil, MCT oil (medium chain triglycerides), sunflower oil, high oleic sunflower oil, palm and palm kernel oils, palm olein, canola oil, marine oils, cottonseed oils, and combinations thereof.
Vitamins and similar other ingredients suitable for use in the base formulas include vitamin A, vitamin D, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, vitamin B12, niacin, folic acid, pantothenic acid, biotin, vitamin C, choline, inositol, salts and derivatives thereof, and combinations thereof. Minerals suitable for use in
the base formulas include calcium, phosphorus, magnesium, iron, zinc, manganese, copper, chromium, iodine, sodium, potassium, chloride, and combinations thereof.
Preferred probiotics for use in an infant formula include those capable of promoting the development of an early bifidogenic intestinal microbiota, e.g. the strains disclosed in EP 1974734.
A pharmaceutical composition as provided herein, e.g. clinical product, and nutritional compositions of the invention, e. g. dietary supplements, may be provided in the form of soft gel, sachets, powders, syrups, liquid suspensions, emulsions and solutions in convenient dosage forms. Oral pharmaceutical or dietary supplement forms may be made by conventional compounding procedures known in the pharmaceutical art, that is, by mixing the active substances together with edible pharmaceutical acceptable solid or liquid carriers and/or excipients, e. g. fillers such as cellulose, lactose, sucrose, mannitol, sorbitol, and calcium phosphates and binders, such as starch, gelatin, tragacanth, methylcellulose and/or polyvinylpyrrolidone (PVP). Optional additives include lubricants and flow conditioners, e. g. silicic acid, silicon dioxide, talc, stearic acid, magnesium/calcium stearates, polyethylene glycol (PEG) diluents, disintegrating agents, e. g. starch, carboxymethyl starch, cross-linked PVP, agar, alginic acid and alginates, colouring agents, flavouring agents, and melting agents. Dyes or pigments may be added to the tablets or dragee coatings, for example for identification purposes or to indicate different doses of active ingredient.
A further aspect of the invention relates to the use of a sialyl-oligosaccharide for the manufacture of a dietetic, nutritional of pharmaceutical composition for treating or preventing a condition associated with a reduced amount Bacteroides ssp. in the gastrointestinal tract. The sialyl oligosaccharide is preferably 3'-sialyllactose, 6'- sialyllactose, or a mixture thereof. The prebiotic sialyl oligosaccharide may be used in combination with one or more Bacteroides ssp. such that a synbiotic dietetic, nutritional of pharmaceutical composition is produced. In a specific embodiment, the use of a sialyl-oligosaccharide is provided for the manufacture of an infant formula for reducing the risk of development of overweight or obesity of an infant in later life. The formula may contain any of the components described herein above. The infant formula can be formulated to be administered to an infant of between 0 and 3 months
of age, between 3 and 6 months of age, between 6 and 9 months of age, between 9 and 12 months of age or between 12 and 24 months of age.
Herewith, the invention also provides a method for enhancing the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for overweight or obesity, comprising administering to the animal a composition comprising at least one sialyl oligosaccharide. Preferably, the
enhancement is associated with reduction of energy harvesting. Said enhancement for example comprises an increase in level of one or more of Bactericides spp.
Also within the scope of the present invention is the use of a sialyl
oligosaccharide to enhance the growth of a Bacteriodes spp. such as Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides prevotalla group, Bacteroides thetaiotaomicron and/or Bacteroides vulgatus. In a specific embodiment, it comprises the use of at least one sialyl oligosaccharide to increase the relative abundance of Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron and/or Bacteroides vulgatus. Growth can be in vitro or in vivo. A preferred sialyl oligosaccharide for use as prebiotic for a Bacteriodes spp. is a (partially) purified sialyllactose, such as 3'-sialyllactose, 6'-sialyllactose or a mixture thereof.
LEGEND TO THE FIGURES
Figure 1: Effects of sialyllactose and GOS on micoflora composition of batch cultures inoculated with a pool of adult faeces. The panels show the total amount of bacteria per vessel (A), bacteroides (B), and bifidobacteria (C) numbers quantified by QPCR. Values shown are averages of two separate runs, with error bars indicating the deviation of the mean of the two measurements.
Figure 2: Effects of sialyllactose and GOS on micoflora composition of batch cultures inoculated with a pool of adult faeces. The panels show the amount of bacteroides (A), and bifidobacteria (B) numbers quantified by QPCR. Values shown are values corrected for the growth in each vessel relative to t=0, and are averages of two separate runs, with error bars indicating the bacterial counts of the two separate runs.
Figure 3: Effects of sialyllactose and GOS on micoflora composition of batch cultures inoculated with a pool of infant faeces as described in example 2. The panels show the total amount of bacteria per vessel (A), bacteroides (B), and bifidobacteria (C) numbers quantified by QPCR. Values shown are averages of two separate runs, with error bars indicating the deviation of the mean of the two measurements.
Figure 4 : Effects of sialyllactose and GOS on micoflora composition of batch cultures inoculated with a pool of infant faeces as described in example 2. The panels show the amount of bacteroides (A), and bifidobacteria (B) numbers quantified by QPCR.
Values shown are values corrected for the growth in each vessel relative to t=0, and are averages of two separate runs, with error bars indicating the bacterial counts of the two separate runs.
EXPERIMENTAL SECTION
Example 1: Effect of sialyl oligosaccharide on adult faeces microflora composition.
Improvement of the health of human can be accomplished by selective stimulation of the growth and/or activity of groups of bacteria in the colon. This stimulation can be induced by prebiotics like oligo- and polysaccharides. This example describes a comparison of the selective fermentation of GOS and sialyl-containing
oligosaccharides by adult human microflora. GOS (Vivinal GOS, FrieslandCampma Domo) and sialyllactose (Vivinal SL, FrieslandCampma Domo) were purified in order to make them suitable for use in the in vitro model and to exclude interference with other components like lactose and glucose. A pH-controlled batch fermentation model, which represents the distal part of the colon, was used to measure the effect of the oligosaccharides on the composition of the microflora, and the production of short chain fatty acids and lactate.
Methods
Production of oligosaccharides
Both GOS (Vivinal GOS) and sialyllactose (Vivinal SL) were purified by means of chromatography into purified GOS and purified SL
Faecal Sample Preparation
Faecal samples were obtained from 16 adult volunteers (average BMI 23,4, range 18,0 - 27,8) free of known gastrointestinal disorders. None of the volunteers had taken prebiotic products within a three-month period prior to sampling. Individual faecal samples were diluted to a 1 in 10 weight/weight mixture using 0.1M, pH7, phosphate buffered saline (PBS) (Sigma laboratories, Gillingham, Dorset, UK) at pH7.4 and pooled. The PBS was reduced overnight in an anaerobic cabinet (10% H2, 10% CO2, 80% N2). This mixture was then homogenised for 120 seconds (Seward Stomacher 80 Biomaster), at normal speed, in the stomacher. The faecal slurry was aliquotted and frozen. The faecal slurry was thawed just prior to the start of the experiment and used to inoculate the batch cultures. pH Controlled, Stirred batch cultures
Chemostat nutrient medium was prepared containing the following ingredients: Peptone water 2g/l (Oxoid, Basingstoke, UK), yeast extract 2g/l (Oxoid), NaCl O.lg/1 (Fisher, Loughborough, UK), K2HPO4.3H20 0.05g/l (BDH, Poole, UK), KH2PO4 0.04g/l (BDH), MgS04.7H20 O.Olg/1 (Sigma), CaCl2.2H20 0.005g/l (BDH), NaHCOs 2g/l (Sigma), Tween 80 (BDH) 2ml, Hemin 0.02g/l, Vitamin Ki ΙΟμΙ (Sigma), Cystiene HC1 0.5g/l (Oxoid), Bile Salts 0.5g/l (Oxoid), Resazarin 4ml/l (Sigma), pH7.
The chemostat nutrient medium autoclaved, then aseptically poured into the sterile batch culture vessels. This was left overnight with nitrogen pumping through the vessel to provide an anaerobic environment. 0.5ml of 10% cysteine-HCl was added to aid reduction of the medium. pH meters (Electrolab pH controller, Tewksbury, UK) were set to regulate the vessels between pH6.8 and pH7 by the addition of 0.5M HC1 or 0.5M NaOH. The vessels were maintained at 37°C, and were stirred using magnetic stirrers. The test material (purified GOS or purified SL were added to the vessel to a final concentration of 10 g/1 oligosaccharide just prior to the addition of 15 ml of faecal slurry of a pool of adult faecal samples (10% w/w). The vessels were left
for 24h, with samples taken at 0, 3, 6, 9 and 24h. The samples were centrifuged for 5 min at 13 200 rpm and supernatants and pellet fractions were stored at—20 C until SCFA measurement (supernatants) or DNA preparation for QPCR analysis (pellet). The pH-controlled fermentation experiments were conducted in two independent experiments using samples from the same faeces pool as indicated.
QPCR analyses
DNA was isolated from frozen pellets of fermented faecal samples using the QIAamp DNA Stool Mini Kit (Qiagen). The number of total bacteria and bacteria of specific groups were quantified by quantitative PCR essentially as described in EP1997906 and EP1997907. The primers and probes for the detection of total bacteria,
Escherichia coli, Lactobacilli, Clostridia, Bifidobacteria, and Bacteroides were based on 16S rDNA gene sequences, retrieved by http ://gr eengene s . lfal, go v website. From these sequences forward primers, reverse primers and TaqMan probes were designed using the Primer Express software. To check specificity, the selected primers and probes were compared to all available 16S rDNA gene sequences using the BLAST database search program. Applied Biosystems manufactured primers and probes.
Results
Batch culture fermentation experiments were set up as described above. The results shown in figure 1 show that SL strongly enhances the growth of Bacteroides, and GOS strongly enhances the growth of Bifidobacteria.
During the batch fermentation only a small increase in total bacteria counts was seen, especially in the carbohydrate groups (Figure 1A). As the total number of bacteria increased in each of the vessels, the results are also shown as values corrected for the total bacteria number in each vessel relative to t=0 (Figure 2).
SL was the only compound tested that clearly promoted the growth of bacteroides (figure IB). This was also the case after correction for growth of bacteria in the vessel, but the effect was less prominent (Figures IB and 2A).
A clear stimulatory effect on bifidobacteria was seen in the vessels containing GOS (figure 1C). This was also clear after correction for the total growth of bacteria in the vessels compared to t=0 (Figure 2B). SL had only a minor effect on bifidobacteria
(Figure 1C and 2B) compared to the control. The growth of Clostridia, Lactobacilli and E. coli was not significantly promoted by either SL or GOS.
These results demonstrate that SL can selectively promote the growth of bacteroides in faeces from human adults.
Example 2: Effect of sialyl oligosaccharide on baby faeces microflora composition.
This example demonstrates the effect of oligo- and polysaccharides on the microbial population of baby faeces by in vitro fermentation. The experiments were essentially carried out as described in Example 1, only now with a batch of in vitro prefermented infant faeces. The testgroups included a control vessel, a vessel containing purified GOS (10 g/L oligosaccharide), and a vessel containing purified SL (lOg/L
oligosaccharide). Results
After DNA isolation of the fermented samples the amount of bacteria were
determined and displayed in Figure 3, and as displayed as values corrected for total bacteria growth compared to t=0 in Figure 4.
Figure 3B shows the amounts of Bacteroides present during batch fermentation. Bacteroides were stimulated by SL and GOS when compared to the control fermentation. When corrected for the total bacteria numbers a stimulation of
Bacteroides was most consistent and prominent for SL (Figure 4A). Figure 3A shows that the total growth of bacteria was stimulated by GOS and SL up to a 2-5 fold increase during 24 h. The total bacteria count of control was stable. Figure 3C illustrates that the Bifidobacteria were stimulated by GOS and SL compared to the Bifidobacteria in the control vessel present. After correction for the total bacteria count (Figure 4B), there is an increase of the amount of Bifidobacteria during the first part of the fermentation (till 9 h), whereas in the second part of the fermentation the amount of Bifidobacteria decreased. These results demonstrate that SL can also increase the amount of Bacteroides in infant faeces.
Example 3: Species analysis using DNA-Chip
The prebiotic effect of sialyllactose on Bacteroides outgrowth in batch culture experiments with infant faeces was further investigated using DNA micro array technology (TNO, Zeist, the Netherlands). DNA obtained from the in vitro batch cultures of Example 2 (T=24 h) were subjected to a DNA chip designed for the detection of more than 400 bacterial species. For each species represented on the microarray one or more unique short oligonucleotide sequences from within the 16S rDNA gene were selected. Criteria for sequence selection, apart from being unique, included length and melting temperature. Short oligonucleotide sequences (approx 20 nt) were used with a melting temperature of 60°C according to the Wallace rule for which a one nucleotide mismatch already resulted in an absence (or very strong decrease) of signal after hybridization.
Results are shown in Table 2. The numbers are based on duplicate analysis, and represent the fold increase over background level.
Table 2
Control SL GOS SL+GOS
Bacteroides 6 25 15 15 distasonis
Bacteroides 25 190 125 190 fragilis
Bacteroides 25 150 125 170 ovatus
Bacteroides 15 95 40 65 prevotalla group
Bacteroides 40 180 90 150 thetaiotao micron
Bacteroides 15 180 50 165 vulgatus
Bacteroides 45 165 90 175 species
Bacteroides 10 75 30 55 group
The results shown in Table 2 demonstrate that SL strongly enhances the growth of Bacteroides, in particular B. fragilis, B. thetaiotaomicron and B. vulgatus. The prebiotic effect of SL on Bacteroides was stronger than that exerted by GOS and remained intact when SL was used in combination with the bifidogenic GOS.
Example 4 : Infant formulas
Table 3 shows the composition of three exemplary nutritional formulas according to the invention, e.g. infant formulas for the age group between 0-6 months, for reducing the risk of development of overweight or obesity of an infant in later life.
Table 3: Composition of the formulas (per 100 ml)
Basic Formula A: SL Formula B: Formula C: SL+
SL+GOS probiotics
Energy, kcal 67 67 67 67
Protein (g) 1.4 1.4 1.4 1.4
Carbohydrates
(g) 7.6 7.4 6.7 6.4
Fat (g) 3.5 3.5 3.5 3.5
0.25 (range 0.005 -
Sialyllactose (g) 2.0 g/lOOml) 0.2 0.2
0.5 (range 0.1 -
Vivinal GOS (g) 1.0 g/100 ml) 0.5
Bacteroides (cfu) 10expl2
Claims
Claims
A dietetic, nutritional, nutraceutical or pharmaceutical composition, comprising:
- at least one sialyloligosaccharide in an amount effective to increase the relative abundance of Bacteroides ssp. in the gastrointestinal tract of an animal, preferably a human; and
- living Bacteroides ssp in an amount of at least 10 exp5 cfu/g dry weight composition.
Composition according to claim 1, wherein said at least one
sialyloligosaccharide is present in an amount effective to increase the relative abundance of Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides prevotalla group, Bacteroides thetaiotao micron, Bacteroides vulgatus or a combination thereof.
Composition according to claim 1 or 2, comprising one or more
sialyloligosaccharides selected from the group consisting of disialyllacto-iV- tetraose, 3'-sialyllactose, 6'-sialyllactose, 3'-sialyllactosamine, 6'- sialyllactosamine, 3'-sialyl-3-fucosyllactose, sialyllacto-iV-tetraose a, sialyllacto-iV-tetraose b, sialyllacto-iV-tetraose c, disialyllactose, 3'-sialyl Lewis A, 3'-sialyl Lewis X, disialyllacto-N-hexaose I, disialyllacto-N-hexaose II, sialyl Lea tetra, sialyllacto-N-neotetraose c, disialyllacto-N-fucopentaose II.
Composition according to claim 3, comprising 3'-sialyllactose and/or 6'- sialyllactose.
Composition according to any one of claims 1 to 4, comprising said at least one sialyloligosaccharide in an amount of 0.005 - 20 grams per dose unit, preferably 0.01— 10 grams per dose unit.
6. Composition according to any of the preceding claims, wherein said
composition is formulated as an infant formula.
Composition according to any of the preceding claims, wherein said Bacteroides ssp. is Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus,
Bacteroides prevotalla group, Bacteroides thetaiotao micron, Bacteroides vulgatus or a combination thereof.
Composition according to any one of the preceding claims, wherein the total amount of living Bacteroides ssp. is 10 exp6 cfu/g dry weight of formula, preferably 10 exp 7 cfu/g
Composition according to any one of the preceding claims, further comprising one or more prebiotics, preferably selected from the group consisting of fructo- oligosaccharides (FOS), galacto-oligosaccharides (GOS), inulin, fucose- containing oligosaccharides, beta glycans, carob flour, gums, pectins, galactans with short or long chains, glucosamine-containing oligosaccharides and nucleotides, more preferably GOS.
10. Composition according to any one of the preceding claims, comprising at least one further milk- or whey- derived compound, preferably a compound selected from the group consisting of sialic acid, a-Lactalbumin, lactoferrin,
glycoprotein, casein macropeptide, gangliosides, phospholipids, colostrum, immunoglobulins, milk calcium and nucleotides.
11. Composition according to any of the preceding claims, for use in the treatment or prevention of overweight or obesity in a human subject.
12. Use of at least one sialyloligosaccharide for the manufacture of a dietetic, nutraceutical, nutritional or pharmaceutical composition for treating or preventing a condition associated with a reduced amount of Bacteroides ssp. the gastrointestinal tract.
13. Use according to claim 11, wherein said condition is overweight or obesity.
14. Use according to claim 11 or 12, wherein said at least one sialyloligosaccharide is selected from the group consisting of disialyllacto-iV-tetraose, 3'-sialyllactose, 6'-sialyllactose, 3'-sialyllactosamine, 6'-sialyllactosamine, 3'-sialyl-3- fucosyllactose, sialyllacto-iV-tetraose a, sialyllacto-iV-tetraose b, sialyllacto-iV- tetraose c, disialyllactose, 3'-sialyl Lewis A, 3'-sialyl Lewis X, disialyllacto-N- hexaose I, disialyllacto-N-hexaose II, sialyl Lea tetra, sialyllacto-N-neotetraose c, disialyllacto-N-fucopentaose II.
15. Use according to claim 13, wherein said sialyloligosaccharide is 3'-sialyllactose, 6'-sialyllactose, or a mixture thereof.
16. Use according to any one of claims 11 to 14, wherein said composition further comprises Bacteroides ssp.
17. Use according to any one of claims 11- 15 for the manufacture of an infant
formula.
18. Use according to claim 16, wherein said infant formula is an infant formula, a follow on formula or a growing up milk, formulated to be administered to human being between 0 and 6 years, preferably an infant formula formulated for infants between 0 and 6 months of age.
19. Use according to claim 16 or 17, for the manufacture of an infant formula for reducing the risk of development of overweight or obesity of an infant in later life.
20. Use of a sialyloligosaccharide to enhance the growth of a Bacteroides spp.
21. Use of a sialyloligosaccharide according to claim 19, wherein said
sialyloligosaccharide is 3'-sialyllactose, 6'-sialyllactose or a mixture thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2004200 | 2010-02-05 | ||
NL2004200A NL2004200C2 (en) | 2010-02-05 | 2010-02-05 | Use of sialyl oligosaccharides in weight management. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011096808A1 true WO2011096808A1 (en) | 2011-08-11 |
Family
ID=42340788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2011/050078 WO2011096808A1 (en) | 2010-02-05 | 2011-02-04 | Use of sialyl oligosaccharides in weight management |
Country Status (2)
Country | Link |
---|---|
NL (1) | NL2004200C2 (en) |
WO (1) | WO2011096808A1 (en) |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2332552A2 (en) * | 2008-08-01 | 2011-06-15 | Benebiosis Co., Ltd. | Composition for prevention or treatment of hyperlipidemia, fatty liver or obesity |
WO2012107865A3 (en) * | 2011-02-10 | 2012-11-01 | Wyeth Llc | Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk |
EP2745705A1 (en) * | 2012-12-18 | 2014-06-25 | Abbott Laboratories | Nutritional use of human milk oligosaccharides |
WO2015003001A1 (en) * | 2013-07-01 | 2015-01-08 | The Washington University | Methods for identifying supplements that increase gut colonization by an isolated bacterial species, and compositions derived therefrom |
EP2885977A1 (en) * | 2013-12-19 | 2015-06-24 | Agriculture and Food Development Authority (TEAGASC) | An oligosaccharide-enriched composition having immune-modulatory and anti-adhesion properties |
WO2016026684A1 (en) * | 2014-08-18 | 2016-02-25 | Nestec S.A. | Prebiotics for reducing the risk of obesity later in life |
WO2017020786A1 (en) * | 2015-07-31 | 2017-02-09 | 广州知易生物科技有限公司 | Application of bacteroides fragilis in treating and/or preventing obesity or diabetes |
US20170136049A1 (en) * | 2011-05-13 | 2017-05-18 | Glycosyn LLC | Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics |
CN106852938A (en) * | 2015-12-09 | 2017-06-16 | 深圳华大基因研究院 | Application of the bacteroid (Bacteroides) in obesity-related disease is treated and prevented |
WO2017129639A1 (en) * | 2016-01-26 | 2017-08-03 | Nestec S.A. | Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat a health disorder by increasing glp-1 secretion |
WO2017129641A1 (en) * | 2016-01-26 | 2017-08-03 | Nestec S.A. | Compositions comprising sialylated oligosaccharides for use in infants or young children to prevent later in life obesity or related comorbidities and promote a healthy growth |
EP3229812A4 (en) * | 2014-12-08 | 2018-10-03 | Glycom A/S | Synthetic composition for treating metabolic disorders |
WO2019002612A1 (en) | 2017-06-30 | 2019-01-03 | N.V. Nutricia | Synbiotic composition for preventing metabolic disorders |
WO2019002607A1 (en) | 2017-06-30 | 2019-01-03 | N.V. Nutricia | Synbiotic composition for preventing disorders |
US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10610548B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
WO2021011905A1 (en) * | 2019-07-18 | 2021-01-21 | The Regents Of The University Of California | Human milk oligosaccharides for control of dietary response and metabolic phenotype |
US10920283B2 (en) | 2013-11-01 | 2021-02-16 | Washington University | Methods to establish and restore normal gut microbiota function of subject in need thereof |
US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
US11890293B2 (en) | 2014-12-08 | 2024-02-06 | Glycom A/S | Synthetic composition for treating metabolic disorders |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060346A2 (en) * | 2000-02-17 | 2001-08-23 | Wyeth | Nutritional formulation containing prebiotic substances |
WO2007043933A1 (en) | 2005-10-07 | 2007-04-19 | Arla Foods Amba | Probiotics to influence fat metabolism and obesity |
WO2007101675A1 (en) | 2006-03-07 | 2007-09-13 | Nestec S.A. | Synbiotic mixture |
WO2008056983A1 (en) | 2006-11-09 | 2008-05-15 | Friesland Brands B.V. | Probiotic (infant) food |
WO2008076696A2 (en) | 2006-12-18 | 2008-06-26 | Washington University In St. Louis | The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder |
EP1974734A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics for reduction of risk of obesity |
EP1997906A1 (en) | 2007-06-01 | 2008-12-03 | Friesland Brands B.V. | Lactobacillus |
EP1997907A1 (en) | 2007-06-01 | 2008-12-03 | Friesland Brands B.V. | Bifidobacteria |
WO2009113861A2 (en) | 2008-03-14 | 2009-09-17 | Friesland Brands B.V. | Process for isolating sialic acid containing oligosaccharides, and the compositions containing sialic acid containing oligosaccharides obtainable thereby |
WO2010002241A1 (en) | 2008-06-30 | 2010-01-07 | N.V. Nutricia | Nutritional composition for infants delivered via caesarean section |
EP2143341A1 (en) | 2008-07-08 | 2010-01-13 | Nestec S.A. | Nutritional Composition Containing Oligosaccharide Mixture |
-
2010
- 2010-02-05 NL NL2004200A patent/NL2004200C2/en not_active IP Right Cessation
-
2011
- 2011-02-04 WO PCT/NL2011/050078 patent/WO2011096808A1/en active Application Filing
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060346A2 (en) * | 2000-02-17 | 2001-08-23 | Wyeth | Nutritional formulation containing prebiotic substances |
WO2007043933A1 (en) | 2005-10-07 | 2007-04-19 | Arla Foods Amba | Probiotics to influence fat metabolism and obesity |
WO2007101675A1 (en) | 2006-03-07 | 2007-09-13 | Nestec S.A. | Synbiotic mixture |
WO2008056983A1 (en) | 2006-11-09 | 2008-05-15 | Friesland Brands B.V. | Probiotic (infant) food |
WO2008076696A2 (en) | 2006-12-18 | 2008-06-26 | Washington University In St. Louis | The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder |
EP1974734A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics for reduction of risk of obesity |
EP1997906A1 (en) | 2007-06-01 | 2008-12-03 | Friesland Brands B.V. | Lactobacillus |
EP1997907A1 (en) | 2007-06-01 | 2008-12-03 | Friesland Brands B.V. | Bifidobacteria |
WO2009113861A2 (en) | 2008-03-14 | 2009-09-17 | Friesland Brands B.V. | Process for isolating sialic acid containing oligosaccharides, and the compositions containing sialic acid containing oligosaccharides obtainable thereby |
WO2010002241A1 (en) | 2008-06-30 | 2010-01-07 | N.V. Nutricia | Nutritional composition for infants delivered via caesarean section |
EP2143341A1 (en) | 2008-07-08 | 2010-01-13 | Nestec S.A. | Nutritional Composition Containing Oligosaccharide Mixture |
Non-Patent Citations (6)
Title |
---|
ASAKUMA ET AL., BIOSCI BIOTECHNOL BIOCHEM., vol. 71, 2007, pages 1447 - 51 |
BALLONGUE ET AL., SCAND J GASTROENTEROL, vol. 32, 1997, pages 41 - 4 |
GIBSON ET AL., GASTROENTEROLOGY, vol. 108, 1995, pages 975 - 82 |
KUNZ ET AL., ANNU REV NUTR., vol. 20, 2000, pages 699 - 722 |
PARNELLREIMER, AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 89, no. 6, June 2009 (2009-06-01), pages 1751 - 1759 |
TANAKA ET AL., BIF. MICROFLORA, vol. 2, 1983, pages 17 - 24 |
Cited By (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2332552A4 (en) * | 2008-08-01 | 2012-04-04 | Benebiosis Co Ltd | Composition for prevention or treatment of hyperlipidemia, fatty liver or obesity |
EP2332552A2 (en) * | 2008-08-01 | 2011-06-15 | Benebiosis Co., Ltd. | Composition for prevention or treatment of hyperlipidemia, fatty liver or obesity |
AU2019261707B8 (en) * | 2009-06-19 | 2022-02-17 | Société des Produits Nestlé S.A. | Prebiotics for reducing the risk of obesity later in life |
AU2019261707B9 (en) * | 2009-06-19 | 2022-02-17 | Société des Produits Nestlé S.A. | Prebiotics for reducing the risk of obesity later in life |
AU2019261707B2 (en) * | 2009-06-19 | 2021-09-30 | Société des Produits Nestlé S.A. | Prebiotics for reducing the risk of obesity later in life |
WO2012107865A3 (en) * | 2011-02-10 | 2012-11-01 | Wyeth Llc | Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk |
US20170136049A1 (en) * | 2011-05-13 | 2017-05-18 | Glycosyn LLC | Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics |
US10286001B2 (en) * | 2011-05-13 | 2019-05-14 | Glycosyn LLC | Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics |
US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
WO2014100225A1 (en) * | 2012-12-18 | 2014-06-26 | Abbott Laboratories | Nutritional use of human milk oligosaccharides |
EP2745705A1 (en) * | 2012-12-18 | 2014-06-25 | Abbott Laboratories | Nutritional use of human milk oligosaccharides |
US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
US11414463B2 (en) | 2013-04-10 | 2022-08-16 | 4D Pharma Research Limited | Polypeptide and immune modulation |
WO2015003001A1 (en) * | 2013-07-01 | 2015-01-08 | The Washington University | Methods for identifying supplements that increase gut colonization by an isolated bacterial species, and compositions derived therefrom |
US10920283B2 (en) | 2013-11-01 | 2021-02-16 | Washington University | Methods to establish and restore normal gut microbiota function of subject in need thereof |
EP2885977A1 (en) * | 2013-12-19 | 2015-06-24 | Agriculture and Food Development Authority (TEAGASC) | An oligosaccharide-enriched composition having immune-modulatory and anti-adhesion properties |
WO2016026684A1 (en) * | 2014-08-18 | 2016-02-25 | Nestec S.A. | Prebiotics for reducing the risk of obesity later in life |
US11406650B2 (en) | 2014-08-18 | 2022-08-09 | Societe Des Produits Nestle S.A. | Prebiotics for reducing the risk of obesity later in life |
CN106659226A (en) * | 2014-08-18 | 2017-05-10 | 雀巢产品技术援助有限公司 | Prebiotics for reducing the risk of obesity later in life |
RU2699981C2 (en) * | 2014-08-18 | 2019-09-11 | Сосьете Де Продюи Нестле С.А. | Prebiotics for reducing risk of developing obesity in later life |
EP3229812A4 (en) * | 2014-12-08 | 2018-10-03 | Glycom A/S | Synthetic composition for treating metabolic disorders |
US11529364B2 (en) | 2014-12-08 | 2022-12-20 | Glycom A/S | Synthetic composition for treating metabolic disorders |
US11890293B2 (en) | 2014-12-08 | 2024-02-06 | Glycom A/S | Synthetic composition for treating metabolic disorders |
US10828313B2 (en) | 2014-12-08 | 2020-11-10 | Glycom A/S | Synthetic composition for treating metabolic disorders |
US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
US10973872B2 (en) | 2014-12-23 | 2021-04-13 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
US10780134B2 (en) | 2015-06-15 | 2020-09-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11389493B2 (en) | 2015-06-15 | 2022-07-19 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11433106B2 (en) | 2015-06-15 | 2022-09-06 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11331352B2 (en) | 2015-06-15 | 2022-05-17 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11273185B2 (en) | 2015-06-15 | 2022-03-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11040075B2 (en) | 2015-06-15 | 2021-06-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10744167B2 (en) | 2015-06-15 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10864236B2 (en) | 2015-06-15 | 2020-12-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
WO2017020786A1 (en) * | 2015-07-31 | 2017-02-09 | 广州知易生物科技有限公司 | Application of bacteroides fragilis in treating and/or preventing obesity or diabetes |
US11058732B2 (en) | 2015-11-20 | 2021-07-13 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
CN106852938A (en) * | 2015-12-09 | 2017-06-16 | 深圳华大基因研究院 | Application of the bacteroid (Bacteroides) in obesity-related disease is treated and prevented |
WO2017129641A1 (en) * | 2016-01-26 | 2017-08-03 | Nestec S.A. | Compositions comprising sialylated oligosaccharides for use in infants or young children to prevent later in life obesity or related comorbidities and promote a healthy growth |
WO2017129639A1 (en) * | 2016-01-26 | 2017-08-03 | Nestec S.A. | Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat a health disorder by increasing glp-1 secretion |
CN108495638A (en) * | 2016-01-26 | 2018-09-04 | 雀巢产品技术援助有限公司 | For baby or child to prevent fat or relevant comorbidities in the future and promote the composition for including sialylated oligosaccharide of healthy growth |
RU2744580C2 (en) * | 2016-01-26 | 2021-03-11 | Сосьете Де Продюи Нестле С.А. | Compositions containing sialylated oligosaccharides for use in infants or young children to prevent obesity in later life or related comorbidities and to promote normal growth |
CN108495634A (en) * | 2016-01-26 | 2018-09-04 | 雀巢产品技术援助有限公司 | For preventing or treating the composition for including human milk oligosaccharides of the healthy obstacle of baby or child by increasing GLP-1 secretions |
US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10610549B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Composition comprising bacterial strains |
US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10960031B2 (en) | 2016-07-13 | 2021-03-30 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10610548B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10967010B2 (en) | 2016-07-13 | 2021-04-06 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10898526B2 (en) | 2016-12-12 | 2021-01-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10543238B2 (en) | 2016-12-12 | 2020-01-28 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11376284B2 (en) | 2017-05-22 | 2022-07-05 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11382936B2 (en) | 2017-05-22 | 2022-07-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
US11660319B2 (en) | 2017-06-14 | 2023-05-30 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11779613B2 (en) | 2017-06-14 | 2023-10-10 | Cj Bioscience, Inc. | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
WO2019002612A1 (en) | 2017-06-30 | 2019-01-03 | N.V. Nutricia | Synbiotic composition for preventing metabolic disorders |
WO2019002607A1 (en) | 2017-06-30 | 2019-01-03 | N.V. Nutricia | Synbiotic composition for preventing disorders |
WO2019002609A1 (en) | 2017-06-30 | 2019-01-03 | N.V. Nutricia | Synbiotic composition for preventing metabolic disorders |
EP4159224A1 (en) | 2017-06-30 | 2023-04-05 | N.V. Nutricia | Synbiotic composition for preventing chronic inflammation |
US11638729B2 (en) | 2017-06-30 | 2023-05-02 | N.V. Nutricia | Synbiotic composition for preventing disorders |
US11638438B2 (en) | 2017-06-30 | 2023-05-02 | N.V. Nutricia | Synbiotic composition for preventing metabolic disorders |
US11641868B2 (en) | 2017-06-30 | 2023-05-09 | N.V. Nutricia | Synbiotic composition for preventing metabolic disorders |
WO2021011905A1 (en) * | 2019-07-18 | 2021-01-21 | The Regents Of The University Of California | Human milk oligosaccharides for control of dietary response and metabolic phenotype |
Also Published As
Publication number | Publication date |
---|---|
NL2004200C2 (en) | 2011-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL2004200C2 (en) | Use of sialyl oligosaccharides in weight management. | |
NL2004201C2 (en) | Use of sialyl oligosaccharides to modulate the immune system. | |
Russell et al. | Metabolic activities and probiotic potential of bifidobacteria | |
EP2805625B2 (en) | Nutritional composition with prebiotics and probiotics | |
US8591919B2 (en) | Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta -1,4/1,6 linkages | |
Ogueke et al. | Probiotics and prebiotics: Unfolding prospects for better human health | |
TW201242518A (en) | Oligosaccharide mixture and food product comprising this mixture, especially infant formula | |
AU2016102461A4 (en) | Nutritional compositions and infant formulas comprising Bifidobacterium animalis ssp. lactis and optionally a mix of oligosaccharides for inducing a gut microbiota close to the one of breast fed infants | |
CN103797021A (en) | Oligosaccharide mixture and food product comprising this mixture, especially infant formula | |
TW201100537A (en) | Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles | |
MX2008011450A (en) | Synbiotic mixture. | |
AU2009268222A1 (en) | Nutritional composition containing oligosaccharide mixture | |
TW201002216A (en) | Probiotics to improve gut microbiota | |
US20170000810A1 (en) | Nutritional composition to reduce metabolic stress in infants | |
US20230270798A1 (en) | Synbiotic composition | |
US20210330687A1 (en) | Bifidogenic hypoallergenic gos compositions and methods for providing the same involving beta-galactosidase from a strain of lactobacillus delbrueckii ssp bulgaricus | |
US20210244777A1 (en) | Novel bifidobacterium bacteria and composition including novel bifidobacterium bacteria | |
RU2804305C2 (en) | Food composition containing urea and non-digestible oligosaccharides | |
AU2021291045A1 (en) | A nutritional composition comprising 3-hydroxybutyric acid to improve the gastrointestinal barrier | |
WO2021255228A1 (en) | N-acetylspermidine to improve the gastrointestinal barrier | |
US20210392936A1 (en) | Nutritional composition comprising urea and non-digestible oligosaccharides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11704102 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11704102 Country of ref document: EP Kind code of ref document: A1 |